UNSPSC 51151520: Aclatonium napadisilate

This classification denotes a cholinergic agonist with the molecular formula 2C10H20NO4.C10H6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX23434YHQ, chemically known as 2-(2-(acetyloxy)-1-oxopropoxy)-n,n,n-trimethylethanaminium, 1,5-naphthalenedisulfonate (2:1) but generally known as aclatonium napadisilate, which bears US NIH Compound Identifier 41315. European Medicines Agency schedules Aclatonium napadisilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05244MIG.

UNSPSC 51151520 Aclatonium napadisilate, a Commodity code, shows limited recent state and local procurement activity aligned with its nominal pharmaceutical scope. The two recent opportunities on file bear no meaningful connection to aclatonium napadisilate itself: Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems (a public health response product unrelated to the code's named substance), and the Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription fulfillment capabilities without specifying any particular pharmaceutical. The code does not reflect current state and local buying patterns for aclatonium napadisilate, and recent issuers in the pharmaceutical space are addressing opioid response and pharmacy benefit management rather than procurement of this specific active ingredient.

The geographic activity documented here centers on Florida and Texas, with Seminole County pursuing naloxone and deactivation systems through a competitive bid process with quarterly deliveries beginning in 2026, and Texas HHS conducting market research on pharmacy direct-contracting models. Neither issuer is soliciting aclatonium napadisilate, and no recent state or local opportunities name this Commodity code in connection with actual purchasing intent. Firms evaluating this code should note the mismatch between the nominal scope and recent activity: aclatonium napadisilate appears to see little or no state and local demand at present, and the opportunities filed under this code reflect pharmaceutical procurement in adjacent but unrelated domains.